Junshi Biosciences’ sNDA for Toripalimab Plus Disitamab Vedotin in HER2-Expressing Urothelial Carcinoma Accepted by China’s NMPA

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to th...

August 11, 2025 | Monday | News
Anbio Launches Chikungunya Rapid Test and Ultra-Fast PCR System to Strengthen Global Outbreak Response

Anbio Biotechnology has announced the launch of its Chikungunya IgM/IgG Rapid Test, offering clinicians and public health authorities a fast, accessible ...

August 11, 2025 | Monday | News
Janux Therapeutics Achieves $10 Million Milestone as First Patient Dosed in Merck Collaboration Trial

First patient dosed in the lead collaboration program triggers a $10 million milestone payment to Janux Janux Therapeutics, Inc. (Nasdaq: JANX...

August 06, 2025 | Wednesday | News
SERB Pharmaceuticals to Acquire Y-mAbs Therapeutics in $412 Million All-Cash Deal

SERB Pharmaceuticals (“SERB”), a global specialty pharmaceutical company focused on medicines for rare diseases and medical emergencies, and ...

August 06, 2025 | Wednesday | News
Shilpa Medicare Backs Alveolus Bio to Accelerate Inhaled Microbiome Therapeutics for Lung Disease

- Alveolus Bio, a pioneering respiratory drug development biotech company founded by Dr. Vivek Lal from University of Alabama at Birmingham, AL, has anno...

August 04, 2025 | Monday | News
Akeso Doses First Patient in Pivotal Phase III Trial of Ivonescimab for IO-Resistant NSCLC

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its pivotal Phase III clinical study (AK112-305/HARMO...

July 31, 2025 | Thursday | News
IntraBio’s AQNEURSA® Receives Positive CHMP Opinion for Niemann-Pick Type C, Paving Way for European Approval

AQNEURSA® could offer a new frontline treatment for NPC patients in Europe CHMP recommendation based on Phase III pivotal trial data and extensi...

July 31, 2025 | Thursday | News
FDA Approves Apellis’ EMPAVELI® as First-Ever Treatment for Rare Kidney Diseases C3G and IC-MPGN

Apellis Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI® (pegcetacoplan) as the first tre...

July 29, 2025 | Tuesday | News
Candel Therapeutics Secures EMA Orphan Designation for CAN-2409 in Pancreatic Cancer

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological ...

July 28, 2025 | Monday | News
Sanofi Secures EU Approval for Sarclisa + VRd in Transplant-Eligible Newly Diagnosed Multiple Myeloma

Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction treatment significantly improved MRD negativity benefit and pro...

July 28, 2025 | Monday | News
Matchpoint Therapeutics Secures Major Partnership with Novartis for Precision Covalent Inhibitor Development

Matchpoint to receive up to $60 million in upfront payment and research funding, with up to $1 billion in total potential payments, including option ex...

July 25, 2025 | Friday | News
QIAGEN Launches QIAseq xHYB Long Read Panels to Enhance Targeted Genomic Analysis

Expansion of QIAseq portfolio to Long Read Panels enables high-resolution analysis of complex genomic regions using long-read sequencing Supports NG...

July 23, 2025 | Wednesday | News
HMNC and Spruce Launch Phase 2 TAMARIND Trial to Explore Precision Treatment for Depression

HMNC Brain Health (“HMNC”), a global precision psychiatry biopharmaceutical company, in collaboration with Spruce Biosciences, Inc. (OTCQB: S...

July 23, 2025 | Wednesday | News
Rakovina Therapeutics Advances AI-Driven ATR Inhibitors in Fight Against Cancer

Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next...

July 23, 2025 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close